Leavell Investment Management Inc. cut its position in shares of Becton Dickinson and Co (NYSE:BDX) by 11.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,391 shares of the medical instruments supplier’s stock after selling 1,773 shares during the period. Leavell Investment Management Inc.’s holdings in Becton Dickinson and were worth $3,344,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its holdings in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the period. Norges Bank purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at $515,703,000. Morgan Stanley increased its holdings in shares of Becton Dickinson and by 133.0% in the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after acquiring an additional 1,581,829 shares during the period. Mackenzie Financial Corp increased its holdings in shares of Becton Dickinson and by 27.7% in the 4th quarter. Mackenzie Financial Corp now owns 1,943,752 shares of the medical instruments supplier’s stock valued at $437,966,000 after acquiring an additional 421,825 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Becton Dickinson and by 1.9% in the 4th quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after acquiring an additional 355,223 shares during the period. 84.87% of the stock is owned by institutional investors and hedge funds.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 8,309 shares of Becton Dickinson and stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the completion of the sale, the chief executive officer now owns 222,785 shares of the company’s stock, valued at approximately $56,839,137.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ribo Alberto Mas sold 4,808 shares of Becton Dickinson and stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the sale, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is currently owned by insiders.
Shares of BDX stock opened at $240.02 on Wednesday. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The firm has a market cap of $66.24 billion, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 1.74 and a beta of 1.21.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the business earned $2.48 EPS. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, equities research analysts forecast that Becton Dickinson and Co will post 12.08 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.28%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
A number of brokerages have recently issued reports on BDX. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Tuesday. Barclays lifted their price target on Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a report on Monday. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Raymond James cut their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 19th. Finally, TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $256.25.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: Discover Your Risk Tolerance
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.